LORRAIN DANIEL S. (Chief Scientific Officer) sold 2.8% of their position (4.17K shares) of CONTINEUM THERAPEUTICS, INC. on the open market
Open‑market sale worth $54.7K — a minor trim. Review remaining holdings and any 10b5‑1 plan disclosures.
S · 2 sales
Filed: 5/1/2026ACC: 0001628280-26-029435
Officer· Chief Scientific Officer
Since Mar 2026
-4.17K
Net shares
Net seller
$54.7K
Total sold
2
Open market trades
0B · 2S
2
Total transactions
4.17K disposed
Non-Derivative Transactions2
Class A Common Stock
Direct
Shares
−3.87K
Price / share
$13.06
Trade value
$50.54K
% of position
2.6%
5/1/2026
147.71K→143.84K
Class A Common Stock
Direct
Shares
−300.00
Price / share
$13.84
Trade value
$4.15K
% of position
0.2%
5/1/2026
143.84K→143.54K
Total
Net shares
−4.17K
Net value
-$54.69K
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Class A Common Stock Direct | 5/1/2026 | S · Sale | −3.87K | $13.06 | $50.54K | 2.6% | 147.71K | 143.84K |
| Class A Common Stock Direct | 5/1/2026 | S · Sale | −300.00 | $13.84 | $4.15K | 0.2% | 143.84K | 143.54K |
| Total | −4.17K | -$54.69K | ||||||
Derivative Transactions0
No derivative transactions reported
Non-Derivative Holdings (Post-Transaction)1
Class A Common Stock
IndirectShares owned6.84K
Total
6.84K indirect6.84K
| Security Title | Shares Owned | Ownership Type |
|---|---|---|
| Class A Common Stock | 6.84K | Indirect |
| Total | 6.84K | 6.84K indirect |
Derivative Holdings (Post-Transaction)0
No derivative holdings reported